BIOLIFE SOLUTIONS INCBLFSEarnings & Financial Report
Biolife Solutions Inc. develops, manufactures and distributes specialized biopreservation products and cold chain management solutions for the cell and gene therapy, biopharmaceutical and regenerative medicine industries. It offers cryopreservation media, automated thawing systems, and temperature monitoring tools, serving biotech firms, research institutions and clinical labs globally.
Revenue
$18.4M
Gross Profit
N/A
Operating Profit
$-3.3M
Net Profit
$-10.2M
Gross Margin
N/A
Operating Margin
-17.9%
Net Margin
-55.4%
YoY Growth
-51.1%
EPS
$-0.22
BIOLIFE SOLUTIONS INC Q1 FY2024 Financial Summary
BIOLIFE SOLUTIONS INC reported revenue of $18.4M (down 51.1% YoY) for Q1 FY2024, with a net profit of $-10.2M (up 25.5% YoY) (-55.4% margin).
Key Financial Metrics
| Total Revenue | $18.4M |
|---|---|
| Net Profit | $-10.2M |
| Gross Margin | N/A |
| Operating Margin | -17.9% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
BIOLIFE SOLUTIONS INC Q1 FY2024 revenue of $18.4M breaks down across 3 segments, led by Product Cell Processing at $16.2M (87.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product Cell Processing | $16.2M | 87.8% |
| Storage And Storage Services Rental Revenue | $1.8M | 10.0% |
| Other | $411.0K | 2.2% |
BIOLIFE SOLUTIONS INC Annual Revenue by Year
BIOLIFE SOLUTIONS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $96.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $96.2M |
| 2024 | $74.6M |
| 2023 | $68.0M |
| 2022 | $76.2M |
BIOLIFE SOLUTIONS INC Quarterly Revenue & Net Profit History
BIOLIFE SOLUTIONS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $18.8M | +24.3% | $11.1M | 58.9% |
| Q3 FY2025 | $28.1M | +31.2% | $621.0K | 2.2% |
| Q2 FY2025 | $25.4M | +28.9% | $-15.8M | -62.3% |
| Q1 FY2025 | $23.9M | +29.9% | $-448.0K | -1.9% |
| Q4 FY2024 | $15.1M | +167.2% | $12.5M | 82.5% |
| Q3 FY2024 | $21.4M | -9.3% | $-1.7M | -8.0% |
| Q2 FY2024 | $19.7M | -32.6% | $-20.7M | -105.1% |
| Q1 FY2024 | $18.4M | -51.1% | $-10.2M | -55.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.4M | $19.7M | $21.4M | $15.1M | $23.9M | $25.4M | $28.1M | $18.8M |
| YoY Growth | -51.1% | -32.6% | -9.3% | 167.2% | 29.9% | 28.9% | 31.2% | 24.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $401.6M | $375.0M | $381.7M | $399.5M | $395.1M | $387.2M | $392.1M | $405.9M |
| Liabilities | $68.2M | $53.5M | $56.2M | $50.6M | $42.5M | $40.1M | $38.3M | $34.0M |
| Equity | $333.4M | $321.4M | $325.5M | $348.9M | $352.6M | $347.2M | $353.7M | $371.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.5M | $6.5M | $4.8M | $1.6M | $1.7M | $7.4M | $6.1M | $4.9M |